-
1
-
-
79959699571
-
Rethinking herpes simplex virus: The way to oncolytic agents
-
PMID:21626603
-
Campadelli-Fiume G, De Giovanni C, Gatta V, Nanni P, Lollini PL, Menotti L. Rethinking herpes simplex virus: the way to oncolytic agents. Revi Med Virol 2011; 21:213-26; PMID:21626603; http://dx. doi. org/10. 1002/rmv. 691
-
(2011)
Revi Med Virol
, vol.21
, pp. 213-226
-
-
Campadelli-Fiume, G.1
De Giovanni, C.2
Gatta, V.3
Nanni, P.4
Lollini, P.L.5
Menotti, L.6
-
2
-
-
33645787026
-
Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor
-
PMID:16554374
-
Zhou G, Roizman B. Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor. Proc Natl Acad Sci U S A 2006; 103:5508-13; PMID:16554374; http://dx. doi. org/10. 1073/pnas. 0601258103
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 5508-5513
-
-
Zhou, G.1
Roizman, B.2
-
3
-
-
53749099520
-
Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2
-
PMID:18684832
-
Menotti L, Cerretani A, Hengel H, Campadelli- Fiume G. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J Virol 2008; 82:10153-61; PMID:18684832; http:// dx. doi. org/10. 1128/JVI. 01133-08
-
(2008)
J Virol
, vol.82
, pp. 10153-10161
-
-
Menotti, L.1
Cerretani, A.2
Hengel, H.3
Campadelli-Fiume, G.4
-
4
-
-
0037069501
-
Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction
-
PMID:12417744
-
Zhou G, Ye GJ, Debinski W, Roizman B. Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci U S A 2002; 99:15124-9; PMID:12417744; http://dx. doi. org/10. 1073/pnas. 232588699
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 15124-15129
-
-
Zhou, G.1
Ye, G.J.2
Debinski, W.3
Roizman, B.4
-
5
-
-
33646746200
-
A herpes simplex virus recombinant that exhibits a singlechain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors
-
PMID:16699034
-
Menotti L, Cerretani A, Campadelli-Fiume G. A herpes simplex virus recombinant that exhibits a singlechain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors. J Virol 2006; 80:5531-9; PMID:16699034; http://dx. doi. org/10. 1128/JVI. 02725-05
-
(2006)
J Virol
, vol.80
, pp. 5531-5539
-
-
Menotti, L.1
Cerretani, A.2
Campadelli-Fiume, G.3
-
6
-
-
77955925502
-
Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells
-
PMID:20508670
-
Grandi P, Fernandez J, Szentirmai O, Carter R, Gianni D, Sena-Esteves M, Breakefield XO. Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells. Cancer Gene Ther 2010; 17:655-63; PMID:20508670; http://dx. doi. org/10. 1038/cgt. 2010. 22
-
(2010)
Cancer Gene Ther
, vol.17
, pp. 655-663
-
-
Grandi, P.1
Fernandez, J.2
Szentirmai, O.3
Carter, R.4
Gianni, D.5
Sena-Esteves, M.6
Breakefield, X.O.7
-
7
-
-
16844366956
-
An oncolytic HSV-1 mutant expressing ICP34. 5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor
-
PMID:15805284
-
Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34. 5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005; 65:2832-9; PMID:15805284; http://dx. doi. org/10. 1158/0008-5472. CAN-04-3227
-
(2005)
Cancer Res
, vol.65
, pp. 2832-2839
-
-
Kambara, H.1
Okano, H.2
Chiocca, E.A.3
Saeki, Y.4
-
8
-
-
85017731934
-
-
Amgen. http://www. amgen. com/media/media_pr_de tail. jsp?releaseID=1962767
-
Amgen
-
-
-
9
-
-
0034922940
-
Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates
-
PMID:11387063
-
Varghese S, Newsome JT, Rabkin SD, McGeagh K, Mahoney D, Nielsen P, Todo T, Martuza RL. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther 2001; 12:999-1010; PMID:11387063; http://dx. doi. org/10. 1089/ 104303401750195944
-
(2001)
Hum Gene Ther
, vol.12
, pp. 999-1010
-
-
Varghese, S.1
Newsome, J.T.2
Rabkin, S.D.3
McGeagh, K.4
Mahoney, D.5
Nielsen, P.6
Todo, T.7
Martuza, R.L.8
-
10
-
-
9944246008
-
Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates
-
PMID:15306839
-
Wolfe D, Niranjan A, Trichel A, Wiley C, Ozuer A, Kanal E, Kondziolka D, Krisky D, Goss J, Deluca N, et al. Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates. Gene Ther 2004; 11:1675-84; PMID:15306839; http://dx. doi. org/10. 1038/sj. gt. 3302336
-
(2004)
Gene Ther
, vol.11
, pp. 1675-1684
-
-
Wolfe, D.1
Niranjan, A.2
Trichel, A.3
Wiley, C.4
Ozuer, A.5
Kanal, E.6
Kondziolka, D.7
Krisky, D.8
Goss, J.9
Deluca, N.10
-
11
-
-
12944315014
-
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
-
PMID:10845725
-
Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7:867-74; PMID:10845725; http:// dx. doi. org/10. 1038/sj. gt. 3301205
-
(2000)
Gene Ther
, vol.7
, pp. 867-874
-
-
Markert, J.M.1
Medlock, M.D.2
Rabkin, S.D.3
Gillespie, G.Y.4
Todo, T.5
Hunter, W.D.6
Palmer, C.A.7
Feigenbaum, F.8
Tornatore, C.9
Tufaro, F.10
-
12
-
-
58149237728
-
Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM
-
PMID:18957964
-
Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2009; 17:199-207; PMID:18957964; http://dx. doi. org/ 10. 1038/mt. 2008. 228
-
(2009)
Mol Ther
, vol.17
, pp. 199-207
-
-
Markert, J.M.1
Liechty, P.G.2
Wang, W.3
Gaston, S.4
Braz, E.5
Karrasch, M.6
Nabors, L.B.7
Markiewicz, M.8
Lakeman, A.D.9
Palmer, C.A.10
-
13
-
-
33845336115
-
A phase I study of OncoVEXGMCSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
-
PMID:17121894
-
Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, et al. A phase I study of OncoVEXGMCSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12:6737-47; PMID:17121894; http://dx. doi. org/10. 1158/1078- 0432. CCR-06-0759
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6737-6747
-
-
Hu, J.C.1
Coffin, R.S.2
Davis, C.J.3
Graham, N.J.4
Groves, N.5
Guest, P.J.6
Harrington, K.J.7
James, N.D.8
Love, C.A.9
McNeish, I.10
-
14
-
-
73349133717
-
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factorencoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma
-
PMID:19884534
-
Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factorencoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27:5763-71; PMID:19884534; http://dx. doi. org/10. 1200/JCO. 2009. 24. 3675
-
(2009)
J Clin Oncol
, vol.27
, pp. 5763-5771
-
-
Senzer, N.N.1
Kaufman, H.L.2
Amatruda, T.3
Nemunaitis, M.4
Reid, T.5
Daniels, G.6
Gonzalez, R.7
Glaspy, J.8
Whitman, E.9
Harrington, K.10
-
15
-
-
77955104827
-
Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck
-
PMID:20670951
-
Harrington KJ, Hingorani M, Tanay MA, Hickey J, Bhide SA, Clarke PM, Renouf LC, Thway K, Sibtain A, McNeish IA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 2010; 16:4005-15; PMID:20670951; http://dx. doi. org/ 10. 1158/1078-0432. CCR-10-0196
-
(2010)
Clin Cancer Res
, vol.16
, pp. 4005-4015
-
-
Harrington, K.J.1
Hingorani, M.2
Tanay, M.A.3
Hickey, J.4
Bhide, S.A.5
Clarke, P.M.6
Renouf, L.C.7
Thway, K.8
Sibtain, A.9
McNeish, I.A.10
-
16
-
-
77957844552
-
Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver
-
PMID:20486770
-
Geevarghese SK, Geller DA, de Haan HA, Horer M, Knoll AE, Mescheder A, Nemunaitis J, Reid TR, Sze DY, Tanabe KK, et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther 2010; 21:1119-28; PMID:20486770; http://dx. doi. org/10. 1089/ hum. 2010. 020
-
(2010)
Hum Gene Ther
, vol.21
, pp. 1119-1128
-
-
Geevarghese, S.K.1
Geller, D.A.2
de Haan, H.A.3
Horer, M.4
Knoll, A.E.5
Mescheder, A.6
Nemunaitis, J.7
Reid, T.R.8
Sze, D.Y.9
Tanabe, K.K.10
-
17
-
-
0032821242
-
Mechanism and application of genetic recombination in herpesviruses
-
PMID:10479778
-
Umene K. Mechanism and application of genetic recombination in herpesviruses. Rev Med Virol 1999; 9:171-82; PMID:10479778; http://dx. doi. org/ 10. 1002/(SICI)1099-1654(199907/09)9:3%3c171:: AID-RMV243%3e3. 0. CO;2-A
-
(1999)
Rev Med Virol
, vol.9
, pp. 171-182
-
-
Umene, K.1
-
18
-
-
0031868959
-
The second-site mutation in the herpes simplex virus recombinants lacking the gamma134. 5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha
-
PMID:9696792
-
Cassady KA, Gross M, Roizman B. The second-site mutation in the herpes simplex virus recombinants lacking the gamma134. 5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. J Virol 1998; 72:7005-11; PMID:9696792
-
(1998)
J Virol
, vol.72
, pp. 7005-7011
-
-
Cassady, K.A.1
Gross, M.2
Roizman, B.3
-
19
-
-
57049146779
-
Clinical features and treatment of adenovirus infections
-
PMID:18655013
-
Lenaerts L, De Clercq E, Naesens L. Clinical features and treatment of adenovirus infections. Rev Med Virol 2008; 18:357-74; PMID:18655013; http://dx. doi. org/10. 1002/rmv. 589
-
(2008)
Rev Med Virol
, vol.18
, pp. 357-374
-
-
Lenaerts, L.1
De Clercq, E.2
Naesens, L.3
-
20
-
-
79952945559
-
Oncolytic adenoviruses for the treatment of human cancer: Focus on translational and clinical data
-
PMID:21126047
-
Pesonen S, Kangasniemi L, Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 2011; 8:12-28; PMID:21126047; http://dx. doi. org/ 10. 1021/mp100219n
-
(2011)
Mol Pharm
, vol.8
, pp. 12-28
-
-
Pesonen, S.1
Kangasniemi, L.2
Hemminki, A.3
-
21
-
-
0344188096
-
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
-
PMID:8832876
-
Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274:373-6; PMID:8832876; http://dx. doi. org/10. 1126/science. 274. 5286. 373
-
(1996)
Science
, vol.274
, pp. 373-376
-
-
Bischoff, J.R.1
Kirn, D.H.2
Williams, A.3
Heise, C.4
Horn, S.5
Muna, M.6
Ng, L.7
Nye, J.A.8
Sampson-Johannes, A.9
Fattaey, A.10
-
22
-
-
19944363519
-
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity
-
PMID:15607965
-
O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6:611-23; PMID:15607965; http://dx. doi. org/ 10. 1016/j. ccr. 2004. 11. 012
-
(2004)
Cancer Cell
, vol.6
, pp. 611-623
-
-
O'Shea, C.C.1
Johnson, L.2
Bagus, B.3
Choi, S.4
Nicholas, C.5
Shen, A.6
Boyle, L.7
Pandey, K.8
Soria, C.9
Kunich, J.10
-
23
-
-
0034610723
-
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
-
PMID:10644974
-
Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19:2-12; PMID:10644974; http://dx. doi. org/10. 1038/sj. onc. 1203251
-
(2000)
Oncogene
, vol.19
, pp. 2-12
-
-
Fueyo, J.1
Gomez-Manzano, C.2
Alemany, R.3
Lee, P.S.4
McDonnell, T.J.5
Mitlianga, P.6
Shi, Y.X.7
Levin, V.A.8
Yung, W.K.9
Kyritsis, A.P.10
-
24
-
-
19044386714
-
Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents
-
PMID:12086848
-
Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M, Hermiston T, Giedlin M, McCormick F, Fattaey A. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002; 1:325-37; PMID:12086848; http://dx. doi. org/10. 1016/S1535- 6108(02)00060-0
-
(2002)
Cancer Cell
, vol.1
, pp. 325-337
-
-
Johnson, L.1
Shen, A.2
Boyle, L.3
Kunich, J.4
Pandey, K.5
Lemmon, M.6
Hermiston, T.7
Giedlin, M.8
McCormick, F.9
Fattaey, A.10
-
25
-
-
0036708228
-
Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy
-
PMID:12189522
-
Kim J, Cho JY, Kim JH, Jung KC, Yun CO. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Ther 2002; 9:725-36; PMID:12189522; http://dx. doi. org/ 10. 1038/sj. cgt. 7700494
-
(2002)
Cancer Gene Ther
, vol.9
, pp. 725-736
-
-
Kim, J.1
Cho, J.Y.2
Kim, J.H.3
Jung, K.C.4
Yun, C.O.5
-
26
-
-
0141592775
-
Rasdependent oncolysis with an adenovirus VAI mutant
-
PMID:14500393
-
Cascallo M, Capella G, Mazo A, Alemany R. Rasdependent oncolysis with an adenovirus VAI mutant. Cancer Res 2003; 63:5544-50; PMID:14500393
-
(2003)
Cancer Res
, vol.63
, pp. 5544-5550
-
-
Cascallo, M.1
Capella, G.2
Mazo, A.3
Alemany, R.4
-
27
-
-
84884186952
-
YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells
-
PMID:24044901
-
Mantwill K, Naumann U, Seznec J, Girbinger V, Lage H, Surowiak P, Beier D, Mittelbronn M, Schlegel J, Holm PS. YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells. J Transl Med 2013; 11:216; PMID:24044901; http://dx. doi. org/10. 1186/1479- 5876-11-216
-
(2013)
J Transl Med
, vol.11
, pp. 216
-
-
Mantwill, K.1
Naumann, U.2
Seznec, J.3
Girbinger, V.4
Lage, H.5
Surowiak, P.6
Beier, D.7
Mittelbronn, M.8
Schlegel, J.9
Holm, P.S.10
-
28
-
-
0034077666
-
Replication-selective adenoviruses as oncolytic agents
-
PMID:10749561
-
Heise C, Kirn DH. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000; 105:847-51; PMID:10749561; http://dx. doi. org/10. 1172/ JCI9762
-
(2000)
J Clin Invest
, vol.105
, pp. 847-851
-
-
Heise, C.1
Kirn, D.H.2
-
29
-
-
0142124908
-
Virotherapeutics: Conditionally replicative adenoviruses for viral oncolysis
-
PMID:14501378
-
Nettelbeck DM. Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis. Anticancer Drugs 2003; 14:577-84; PMID:14501378; http://dx. doi. org/10. 1097/00001813-200309000-00001
-
(2003)
Anticancer Drugs
, vol.14
, pp. 577-584
-
-
Nettelbeck, D.M.1
-
30
-
-
76749116217
-
Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo
-
PMID:20085660
-
Li X, Liu Y, Wen Z, Li C, Lu H, Tian M, Jin K, Sun L, Gao P, Yang E, et al. Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo. Mol Cancer 2010; 9:10; PMID:20085660; http://dx. doi. org/10. 1186/1476- 4598-9-10
-
(2010)
Mol Cancer
, vol.9
, pp. 10
-
-
Li, X.1
Liu, Y.2
Wen, Z.3
Li, C.4
Lu, H.5
Tian, M.6
Jin, K.7
Sun, L.8
Gao, P.9
Yang, E.10
-
31
-
-
84899538705
-
A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKs
-
PMID:24722669
-
Gao Q, Chen C, Ji T, Wu P, Han Z, Fang H, Li F, Liu Y, Hu W, Gong D, et al. A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKs. PLoS One 2014; 9:e94050; PMID:24722669; http://dx. doi. org/10. 1371/journal. pone. 0094050
-
(2014)
PLoS One
, vol.9
-
-
Gao, Q.1
Chen, C.2
Ji, T.3
Wu, P.4
Han, Z.5
Fang, H.6
Li, F.7
Liu, Y.8
Hu, W.9
Gong, D.10
-
32
-
-
77957571590
-
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF
-
PMID:20664527
-
Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010; 18:1874-84; PMID:20664527; http://dx. doi. org/10. 1038/ mt. 2010. 161
-
(2010)
Mol Ther
, vol.18
, pp. 1874-1884
-
-
Koski, A.1
Kangasniemi, L.2
Escutenaire, S.3
Pesonen, S.4
Cerullo, V.5
Diaconu, I.6
Nokisalmi, P.7
Raki, M.8
Rajecki, M.9
Guse, K.10
-
33
-
-
84869095632
-
A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer
-
PMID:23088985
-
Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, Aimi J, Lerner S, Yeung AW, Kazarian T, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol 2012; 188:2391-7; PMID:23088985; http://dx. doi. org/10. 1016/j. juro. 2012. 07. 097
-
(2012)
J Urol
, vol.188
, pp. 2391-2397
-
-
Burke, J.M.1
Lamm, D.L.2
Meng, M.V.3
Nemunaitis, J.J.4
Stephenson, J.J.5
Arseneau, J.C.6
Aimi, J.7
Lerner, S.8
Yeung, A.W.9
Kazarian, T.10
-
36
-
-
0036710714
-
The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells
-
PMID:12204675
-
Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, Curiel DT, Douglas JT. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 2002; 38:1917-26; PMID:12204675; http://dx. doi. org/10. 1016/S0959- 8049(02)00131-4
-
(2002)
Eur J Cancer
, vol.38
, pp. 1917-1926
-
-
Kim, M.1
Zinn, K.R.2
Barnett, B.G.3
Sumerel, L.A.4
Krasnykh, V.5
Curiel, D.T.6
Douglas, J.T.7
-
37
-
-
0034980914
-
Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver
-
PMID:11162308
-
Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM, Barsoum J, Fawell SE. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001; 3:28-35; PMID:11162308; http://dx. doi. org/ 10. 1006/mthe. 2000. 0227
-
(2001)
Mol Ther
, vol.3
, pp. 28-35
-
-
Tao, N.1
Gao, G.P.2
Parr, M.3
Johnston, J.4
Baradet, T.5
Wilson, J.M.6
Barsoum, J.7
Fawell, S.E.8
-
38
-
-
0034830243
-
CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors
-
PMID:11571572
-
Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 2001; 8:1347-53; PMID:11571572; http://dx. doi. org/10. 1038/sj. gt. 3301515
-
(2001)
Gene Ther
, vol.8
, pp. 1347-1353
-
-
Alemany, R.1
Curiel, D.T.2
-
39
-
-
0035989025
-
In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor
-
PMID:12027562
-
Smith T, Idamakanti N, Kylefjord H, Rollence M, King L, Kaloss M, Kaleko M, Stevenson SC. In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol Ther 2002; 5:770-9; PMID:12027562; http://dx. doi. org/ 10. 1006/mthe. 2002. 0613
-
(2002)
Mol Ther
, vol.5
, pp. 770-779
-
-
Smith, T.1
Idamakanti, N.2
Kylefjord, H.3
Rollence, M.4
King, L.5
Kaloss, M.6
Kaleko, M.7
Stevenson, S.C.8
-
40
-
-
77957953561
-
Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors
-
PMID:20610817
-
Alba R, Bradshaw AC, Coughlan L, Denby L, McDonald RA, Waddington SN, Buckley SM, Greig JA, Parker AL, Miller AM, et al. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 2010; 116:2656- 64; PMID:20610817; http://dx. doi. org/10. 1182/ blood-2009-12-260026
-
(2010)
Blood
, vol.116
, pp. 2656-2664
-
-
Alba, R.1
Bradshaw, A.C.2
Coughlan, L.3
Denby, L.4
McDonald, R.A.5
Waddington, S.N.6
Buckley, S.M.7
Greig, J.A.8
Parker, A.L.9
Miller, A.M.10
-
41
-
-
77956585904
-
Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor £ binding, decreases liver tropism, and improves antitumor efficacy
-
PMID:20736345
-
Short JJ, Rivera AA, Wu H, Walter MR, Yamamoto M, Mathis JM, Curiel DT. Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor £ binding, decreases liver tropism, and improves antitumor efficacy. Mol Cancer Ther 2010; 9:2536-44; PMID:20736345; http://dx. doi. org/10. 1158/1535-7163. MCT-10-0332
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 2536-2544
-
-
Short, J.J.1
Rivera, A.A.2
Wu, H.3
Walter, M.R.4
Yamamoto, M.5
Mathis, J.M.6
Curiel, D.T.7
-
42
-
-
79952207509
-
Tropism-modification strategies for targeted gene delivery using adenoviral vectors
-
PMID:21994621
-
Coughlan L, Alba R, Parker AL, Bradshaw AC, McNeish IA, Nicklin SA, Baker AH. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2010; 2:2290-355; PMID:21994621; http://dx. doi. org/10. 3390/ v2102290
-
(2010)
Viruses
, vol.2
, pp. 2290-2355
-
-
Coughlan, L.1
Alba, R.2
Parker, A.L.3
Bradshaw, A.C.4
McNeish, I.A.5
Nicklin, S.A.6
Baker, A.H.7
-
43
-
-
84867037132
-
Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer
-
PMID:22871667
-
Hemminki O, Diaconu I, Cerullo V, Pesonen SK, Kanerva A, Joensuu T, Kairemo K, Laasonen L, Partanen K, Kangasniemi L, et al. Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol Ther 2012; 20:1821-30; PMID:22871667; http://dx. doi. org/ 10. 1038/mt. 2012. 115
-
(2012)
Mol Ther
, vol.20
, pp. 1821-1830
-
-
Hemminki, O.1
Diaconu, I.2
Cerullo, V.3
Pesonen, S.K.4
Kanerva, A.5
Joensuu, T.6
Kairemo, K.7
Laasonen, L.8
Partanen, K.9
Kangasniemi, L.10
-
44
-
-
77956836329
-
Development of a targeted gene vector platform based on simian adenovirus serotype 24
-
PMID:20631120
-
Belousova N, Mikheeva G, Xiong C, Soghomonian S, Young D, Le Roux L, Naff K, Bidaut L, Wei W, Li C, et al. Development of a targeted gene vector platform based on simian adenovirus serotype 24. J Virol 2010; 84:10087-101; PMID:20631120; http://dx. doi. org/10. 1128/JVI. 02425-09
-
(2010)
J Virol
, vol.84
, pp. 10087-10101
-
-
Belousova, N.1
Mikheeva, G.2
Xiong, C.3
Soghomonian, S.4
Young, D.5
Le Roux, L.6
Naff, K.7
Bidaut, L.8
Wei, W.9
Li, C.10
-
45
-
-
61649121877
-
Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model
-
PMID:19211122
-
Sharma A, Bangari DS, Tandon M, Pandey A, HogenEsch H, Mittal SK. Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology 2009; 386:44-54; PMID:19211122; http://dx. doi. org/10. 1016/j. virol. 2009. 01. 008
-
(2009)
Virology
, vol.386
, pp. 44-54
-
-
Sharma, A.1
Bangari, D.S.2
Tandon, M.3
Pandey, A.4
HogenEsch, H.5
Mittal, S.K.6
-
46
-
-
49149090311
-
Directed evolution generates a novel oncolytic virus for the treatment of colon cancer
-
PMID:18560559
-
Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, Reid T, Ni S, Lieber A, Fisher K, et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One 2008; 3: e2409; PMID:18560559; http://dx. doi. org/10. 1371/ journal. pone. 0002409
-
(2008)
PLoS One
, vol.3
-
-
Kuhn, I.1
Harden, P.2
Bauzon, M.3
Chartier, C.4
Nye, J.5
Thorne, S.6
Reid, T.7
Ni, S.8
Lieber, A.9
Fisher, K.10
-
47
-
-
84871919798
-
Infectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted library
-
PMID:23032977
-
Miura Y, Yamasaki S, Davydova J, Brown E, Aoki K, Vickers S, Yamamoto M. Infectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted library. Mol Ther 2013; 21:139-48; PMID:23032977; http://dx. doi. org/ 10. 1038/mt. 2012. 205
-
(2013)
Mol Ther
, vol.21
, pp. 139-148
-
-
Miura, Y.1
Yamasaki, S.2
Davydova, J.3
Brown, E.4
Aoki, K.5
Vickers, S.6
Yamamoto, M.7
-
48
-
-
0036828125
-
Hepatic arterial infusion of a replication- selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints
-
PMID:12414631
-
Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, et al. Hepatic arterial infusion of a replication- selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62:6070-9; PMID:12414631
-
(2002)
Cancer Res
, vol.62
, pp. 6070-6079
-
-
Reid, T.1
Galanis, E.2
Abbruzzese, J.3
Sze, D.4
Wein, L.M.5
Andrews, J.6
Randlev, B.7
Heise, C.8
Uprichard, M.9
Hatfield, M.10
-
49
-
-
78049468477
-
A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases
-
PMID:20978148
-
Kimball KJ, Preuss MA, Barnes MN, Wang M, Siegal GP, Wan W, Kuo H, Saddekni S, Stockard CR, Grizzle WE, et al. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res 2010; 16:5277-87; PMID:20978148; http://dx. doi. org/10. 1158/1078-0432. CCR-10-0791
-
(2010)
Clin Cancer Res
, vol.16
, pp. 5277-5287
-
-
Kimball, K.J.1
Preuss, M.A.2
Barnes, M.N.3
Wang, M.4
Siegal, G.P.5
Wan, W.6
Kuo, H.7
Saddekni, S.8
Stockard, C.R.9
Grizzle, W.E.10
-
50
-
-
84857505900
-
Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors
-
PMID:21630267
-
Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, Nokisalmi P, Dotti G, Guse K, Laasonen L, et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer 2012; 130:1937- 47; PMID:21630267; http://dx. doi. org/10. 1002/ ijc. 26216
-
(2012)
Int J Cancer
, vol.130
, pp. 1937-1947
-
-
Pesonen, S.1
Diaconu, I.2
Cerullo, V.3
Escutenaire, S.4
Raki, M.5
Kangasniemi, L.6
Nokisalmi, P.7
Dotti, G.8
Guse, K.9
Laasonen, L.10
-
51
-
-
77954530690
-
Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors
-
PMID:20237509
-
Pesonen S, Nokisalmi P, Escutenaire S, Sarkioja M, Raki M, Cerullo V, Kangasniemi L, Laasonen L, Ribacka C, Guse K, et al. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther 2010; 17:892-904; PMID:20237509; http://dx. doi. org/10. 1038/ gt. 2010. 17
-
(2010)
Gene Ther
, vol.17
, pp. 892-904
-
-
Pesonen, S.1
Nokisalmi, P.2
Escutenaire, S.3
Sarkioja, M.4
Raki, M.5
Cerullo, V.6
Kangasniemi, L.7
Laasonen, L.8
Ribacka, C.9
Guse, K.10
-
52
-
-
79958140936
-
Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients
-
PMID:21520358
-
Raki M, Sarkioja M, Escutenaire S, Kangasniemi L, Haavisto E, Kanerva A, Cerullo V, Joensuu T, Oksanen M, Pesonen S, et al. Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. J Gene Med 2011; 13:253-61; PMID:21520358; http://dx. doi. org/ 10. 1002/jgm. 1565
-
(2011)
J Gene Med
, vol.13
, pp. 253-261
-
-
Raki, M.1
Sarkioja, M.2
Escutenaire, S.3
Kangasniemi, L.4
Haavisto, E.5
Kanerva, A.6
Cerullo, V.7
Joensuu, T.8
Oksanen, M.9
Pesonen, S.10
-
53
-
-
84901035359
-
Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans
-
Aug 1
-
Bramante S, Koski A, Kipar A, Diaconu I, Liikanen I, Hemminki O, Vassilev L, Parviainen S, Cerullo V, Pesonen SK, et al. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int J Cancer. 2014 Aug 1; 135 (3):720-30.
-
(2014)
Int J Cancer.
, vol.135
, Issue.3
, pp. 720-730
-
-
Bramante, S.1
Koski, A.2
Kipar, A.3
Diaconu, I.4
Liikanen, I.5
Hemminki, O.6
Vassilev, L.7
Parviainen, S.8
Cerullo, V.9
Pesonen, S.K.10
-
54
-
-
84882452568
-
A phase I clinical trial of Ad5/ 3-Delta24, a novel serotype-chimeric, infectivityenhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer
-
PMID:23756180
-
Kim KH, Dmitriev IP, Saddekni S, Kashentseva EA, Harris RD, Aurigemma R, Bae S, Singh KP, Siegal GP, Curiel DT, et al. A phase I clinical trial of Ad5/ 3-Delta24, a novel serotype-chimeric, infectivityenhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol 2013; 130:518-24; PMID:23756180; http://dx. doi. org/10. 1016/j. ygyno. 2013. 06. 003
-
(2013)
Gynecol Oncol
, vol.130
, pp. 518-524
-
-
Kim, K.H.1
Dmitriev, I.P.2
Saddekni, S.3
Kashentseva, E.A.4
Harris, R.D.5
Aurigemma, R.6
Bae, S.7
Singh, K.P.8
Siegal, G.P.9
Curiel, D.T.10
-
55
-
-
85017727517
-
Review of the current status of phase I clinical studies of Enadenotucirev (ColoAd1), an Ad11/Ad3 chimeric group B adenovirus, in patients with metastatic epithelial solid tumors
-
th International Conference on Oncolytic Virus Therapeutics 2014
-
(2014)
th International Conference on Oncolytic Virus Therapeutics
-
-
Blanc, C.1
Calvo, E.2
Martin, M.G.3
Machiels, J.P.4
Rottey, S.5
Carbonero, R.G.6
McNeish, I.A.7
Ellis, C.8
Fisher, K.9
Beadle, J.10
-
56
-
-
76349086193
-
A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors
-
PMID:19935775
-
Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, Adams N, Zhang YA, Maples PB, Chen S, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 2010; 18:429-34; PMID:19935775; http://dx. doi. org/ 10. 1038/mt. 2009. 262
-
(2010)
Mol Ther
, vol.18
, pp. 429-434
-
-
Nemunaitis, J.1
Tong, A.W.2
Nemunaitis, M.3
Senzer, N.4
Phadke, A.P.5
Bedell, C.6
Adams, N.7
Zhang, Y.A.8
Maples, P.B.9
Chen, S.10
-
58
-
-
39849092406
-
A phase I trial of Ad. hIFN-beta gene therapy for glioma
-
PMID:18180770
-
Chiocca EA, Smith KM, McKinney B, Palmer CA, Rosenfeld S, Lillehei K, Hamilton A, DeMasters BK, Judy K, Kirn D. A phase I trial of Ad. hIFN-beta gene therapy for glioma. Mol Ther 2008; 16:618-26; PMID:18180770; http://dx. doi. org/10. 1038/sj. mt. 6300396
-
(2008)
Mol Ther
, vol.16
, pp. 618-626
-
-
Chiocca, E.A.1
Smith, K.M.2
McKinney, B.3
Palmer, C.A.4
Rosenfeld, S.5
Lillehei, K.6
Hamilton, A.7
DeMasters, B.K.8
Judy, K.9
Kirn, D.10
-
59
-
-
51649128840
-
Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597
-
PMID:18757331
-
Keedy V, Wang W, Schiller J, Chada S, Slovis B, Coffee K, Worrell J, Thet LA, Johnson DH, Carbone DP. Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597. J Clin Oncol 2008; 26:4166-71; PMID:18757331; http:// dx. doi. org/10. 1200/JCO. 2007. 15. 6927
-
(2008)
J Clin Oncol
, vol.26
, pp. 4166-4171
-
-
Keedy, V.1
Wang, W.2
Schiller, J.3
Chada, S.4
Slovis, B.5
Coffee, K.6
Worrell, J.7
Thet, L.A.8
Johnson, D.H.9
Carbone, D.P.10
-
60
-
-
67650327240
-
Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A pilot phase II trial
-
PMID:19287305
-
Tian G, Liu J, Zhou JS, Chen W. Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. Anticancer Drugs 2009; 20:389- 95; PMID:19287305; http://dx. doi. org/10. 1097/ CAD. 0b013e32832a2df9
-
(2009)
Anticancer Drugs
, vol.20
, pp. 389-395
-
-
Tian, G.1
Liu, J.2
Zhou, J.S.3
Chen, W.4
-
61
-
-
68949197421
-
Phase I and biodistribution study of recombinant adenovirus vectormediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors
-
PMID:19363470
-
Xu F, Li S, Li XL, Guo Y, Zou BY, Xu R, Liao H, Zhao HY, Zhang Y, Guan ZZ, et al. Phase I and biodistribution study of recombinant adenovirus vectormediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors. Cancer Gene Ther 2009; 16:723-30; PMID:19363470; http://dx. doi. org/10. 1038/cgt. 2009. 19
-
(2009)
Cancer Gene Ther
, vol.16
, pp. 723-730
-
-
Xu, F.1
Li, S.2
Li, X.L.3
Guo, Y.4
Zou, B.Y.5
Xu, R.6
Liao, H.7
Zhao, H.Y.8
Zhang, Y.9
Guan, Z.Z.10
-
62
-
-
33947702021
-
Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer
-
discussion . e9-10 PMID:17403430
-
Page JG, Tian B, Schweikart K, Tomaszewski J, Harris R, Broadt T, Polley-Nelson J, Noker PE, Wang M, Makhija S, et al. Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Am J Obstet Gynecol 2007; 196:389. e1-9; discussion . e9-10; PMID:17403430; http://dx. doi. org/10. 1016/j. ajog. 2006. 12. 016
-
(2007)
Am J Obstet Gynecol
, vol.196
, pp. 389.e1-389.e9
-
-
Page, J.G.1
Tian, B.2
Schweikart, K.3
Tomaszewski, J.4
Harris, R.5
Broadt, T.6
Polley-Nelson, J.7
Noker, P.E.8
Wang, M.9
Makhija, S.10
-
63
-
-
0037344533
-
Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients
-
PMID:12601393
-
Griscelli F, Opolon P, Saulnier P, Mami-Chouaib F, Gautier E, Echchakir H, Angevin E, Le Chevalier T, Bataille V, Squiban P, et al. Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients. Gene Ther 2003; 10:386-95; PMID:12601393; http://dx. doi. org/10. 1038/sj. gt. 3301928
-
(2003)
Gene Ther
, vol.10
, pp. 386-395
-
-
Griscelli, F.1
Opolon, P.2
Saulnier, P.3
Mami-Chouaib, F.4
Gautier, E.5
Echchakir, H.6
Angevin, E.7
Le Chevalier, T.8
Bataille, V.9
Squiban, P.10
-
64
-
-
35148855074
-
An inventory of shedding data from clinical gene therapy trials
-
PMID:17880045
-
Schenk-Braat EA, van Mierlo MM, Wagemaker G, Bangma CH, Kaptein LC. An inventory of shedding data from clinical gene therapy trials. J Gene Med 2007; 9:910-21; PMID:17880045; http://dx. doi. org/ 10. 1002/jgm. 1096
-
(2007)
J Gene Med
, vol.9
, pp. 910-921
-
-
Schenk-Braat, E.A.1
van Mierlo, M.M.2
Wagemaker, G.3
Bangma, C.H.4
Kaptein, L.C.5
-
65
-
-
69249213616
-
Computational analysis of human adenovirus type 22 provides evidence for recombination among species D human adenoviruses in the penton base gene
-
PMID:19553309
-
Robinson CM, Rajaiya J, Walsh MP, Seto D, Dyer DW, Jones MS, Chodosh J. Computational analysis of human adenovirus type 22 provides evidence for recombination among species D human adenoviruses in the penton base gene. J Virol 2009; 83:8980-5; PMID:19553309; http://dx. doi. org/10. 1128/ JVI. 00786-09
-
(2009)
J Virol
, vol.83
, pp. 8980-8985
-
-
Robinson, C.M.1
Rajaiya, J.2
Walsh, M.P.3
Seto, D.4
Dyer, D.W.5
Jones, M.S.6
Chodosh, J.7
-
66
-
-
66749181110
-
Evidence of molecular evolution driven by recombination events influencing tropism in a novel human adenovirus that causes epidemic keratoconjunctivitis
-
PMID:19492050
-
Walsh MP, Chintakuntlawar A, Robinson CM, Madisch I, Harrach B, Hudson NR, Schnurr D, Heim A, Chodosh J, Seto D, et al. Evidence of molecular evolution driven by recombination events influencing tropism in a novel human adenovirus that causes epidemic keratoconjunctivitis. PLoS One 2009; 4: e5635; PMID:19492050; http://dx. doi. org/10. 1371/ journal. pone. 0005635
-
(2009)
PLoS One
, vol.4
-
-
Walsh, M.P.1
Chintakuntlawar, A.2
Robinson, C.M.3
Madisch, I.4
Harrach, B.5
Hudson, N.R.6
Schnurr, D.7
Heim, A.8
Chodosh, J.9
Seto, D.10
-
67
-
-
84886303993
-
Homologous recombination in E3 genes of human adenovirus species D
-
PMID:24027303
-
Singh G, Robinson CM, Dehghan S, Jones MS, Dyer DW, Seto D, Chodosh J. Homologous recombination in E3 genes of human adenovirus species D. J Virol 2013; 87:12481-8; PMID:24027303; http://dx. doi. org/10. 1128/JVI. 01927-13
-
(2013)
J Virol
, vol.87
, pp. 12481-12488
-
-
Singh, G.1
Robinson, C.M.2
Dehghan, S.3
Jones, M.S.4
Dyer, D.W.5
Seto, D.6
Chodosh, J.7
-
68
-
-
0037333202
-
Measles: Not just another viral exanthem
-
PMID:12620751
-
Duke T, Mgone CS. Measles: not just another viral exanthem. Lancet 2003; 361:763-73; PMID:12620751; http://dx. doi. org/10. 1016/S0140- 6736(03)12661-X
-
(2003)
Lancet
, vol.361
, pp. 763-773
-
-
Duke, T.1
Mgone, C.S.2
-
69
-
-
58249115335
-
Measles: Old vaccines, new vaccines
-
PMID:19203111
-
Griffin DE, Pan CH. Measles: old vaccines, new vaccines. Curr Top Microbiol Immunol 2009; 330:191- 212; PMID:19203111
-
(2009)
Curr Top Microbiol Immunol
, vol.330
, pp. 191-212
-
-
Griffin, D.E.1
Pan, C.H.2
-
70
-
-
84863543763
-
Attenuated oncolytic measles virus strains as cancer therapeutics
-
PMID:21740361
-
Msaouel P, Iankov ID, Dispenzieri A, Galanis E. Attenuated oncolytic measles virus strains as cancer therapeutics. Curr Pharm Biotechnol 2012; 13:1732- 41; PMID:21740361; http://dx. doi. org/10. 2174/ 138920112800958896
-
(2012)
Curr Pharm Biotechnol
, vol.13
, pp. 1732-1741
-
-
Msaouel, P.1
Iankov, I.D.2
Dispenzieri, A.3
Galanis, E.4
-
71
-
-
48249118805
-
Measles virus as an oncolytic vector platform
-
PMID:18537591
-
Blechacz B, Russell SJ. Measles virus as an oncolytic vector platform. Curr Gene Ther 2008; 8:162-75; PMID:18537591; http://dx. doi. org/10. 2174/ 156652308784746459
-
(2008)
Curr Gene Ther
, vol.8
, pp. 162-175
-
-
Blechacz, B.1
Russell, S.J.2
-
72
-
-
58849107795
-
Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: An overview
-
PMID:19169959
-
Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 2009; 11:43-53; PMID:19169959
-
(2009)
Curr Opin Mol Ther
, vol.11
, pp. 43-53
-
-
Msaouel, P.1
Dispenzieri, A.2
Galanis, E.3
-
73
-
-
76249123546
-
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer
-
PMID:20103634
-
Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ, Jr., Aderca I, Zollman PJ, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010; 70:875-82; PMID:20103634; http://dx. doi. org/ 10. 1158/0008-5472. CAN-09-2762
-
(2010)
Cancer Res
, vol.70
, pp. 875-882
-
-
Galanis, E.1
Hartmann, L.C.2
Cliby, W.A.3
Long, H.J.4
Peethambaram, P.P.5
Barrette, B.A.6
Kaur, J.S.7
Haluska, P.J.8
Aderca, I.9
Zollman, P.J.10
-
74
-
-
84904744363
-
Remission of disseminated cancer after systemic oncolytic virotherapy
-
Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG, Lowe V, O'Connor MK, Kyle RA, Leung N, et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clinic proceedings 2014
-
(2014)
Mayo Clinic proceedings
-
-
Russell, S.J.1
Federspiel, M.J.2
Peng, K.W.3
Tong, C.4
Dingli, D.5
Morice, W.G.6
Lowe, V.7
O'Connor, M.K.8
Kyle, R.A.9
Leung, N.10
-
75
-
-
18644380484
-
Pathogenicity and immunology of Newcastle disease virus (NVD) in man
-
PMID:14376703
-
Evans AS. Pathogenicity and immunology of Newcastle disease virus (NVD) in man. Am J Public Health Nations Health 1955; 45:742-5; PMID:14376703; http://dx. doi. org/10. 2105/AJPH. 45. 6. 742
-
(1955)
Am J Public Health Nations Health
, vol.45
, pp. 742-745
-
-
Evans, A.S.1
-
76
-
-
0037311805
-
Effect of fusion protein cleavage site mutations on virulence of Newcastle disease virus: Non-virulent cleavage site mutants revert to virulence after one passage in chicken brain
-
PMID:12560582
-
de Leeuw OS, Hartog L, Koch G, Peeters BP. Effect of fusion protein cleavage site mutations on virulence of Newcastle disease virus: non-virulent cleavage site mutants revert to virulence after one passage in chicken brain. J Gen Virol 2003; 84:475-84; PMID:12560582; http://dx. doi. org/10. 1099/ vir. 0. 18714-0
-
(2003)
J Gen Virol
, vol.84
, pp. 475-484
-
-
de Leeuw, O.S.1
Hartog, L.2
Koch, G.3
Peeters, B.P.4
-
77
-
-
0033955837
-
Newcastle disease virus (NDV): Brief history of its oncolytic strains
-
PMID:10680736
-
Sinkovics JG, Horvath JC. Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 2000; 16:1-15; PMID:10680736; http://dx. doi. org/10. 1016/S1386-6532(99)00072-4
-
(2000)
J Clin Virol
, vol.16
, pp. 1-15
-
-
Sinkovics, J.G.1
Horvath, J.C.2
-
78
-
-
34548552691
-
Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus
-
PMID:17804743
-
Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF, Martinez-Sobrido L, Woo SL, Garcia-Sastre A. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res 2007; 67:8285-92; PMID:17804743; http://dx. doi. org/10. 1158/0008-5472. CAN-07-1025
-
(2007)
Cancer Res
, vol.67
, pp. 8285-8292
-
-
Vigil, A.1
Park, M.S.2
Martinez, O.3
Chua, M.A.4
Xiao, S.5
Cros, J.F.6
Martinez-Sobrido, L.7
Woo, S.L.8
Garcia-Sastre, A.9
-
79
-
-
67349132360
-
Genetically engineered Newcastle disease virus for malignant melanoma therapy
-
PMID:19242529
-
Zamarin D, Vigil A, Kelly K, Garcia-Sastre A, Fong Y. Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther 2009; 16:796-804; PMID:19242529; http://dx. doi. org/ 10. 1038/gt. 2009. 14
-
(2009)
Gene Ther
, vol.16
, pp. 796-804
-
-
Zamarin, D.1
Vigil, A.2
Kelly, K.3
Garcia-Sastre, A.4
Fong, Y.5
-
80
-
-
63949087329
-
Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses
-
PMID:19209145
-
Zamarin D, Martinez-Sobrido L, Kelly K, Mansour M, Sheng G, Vigil A, Garcia-Sastre A, Palese P, Fong Y. Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther 2009; 17:697-706; PMID:19209145; http://dx. doi. org/ 10. 1038/mt. 2008. 286
-
(2009)
Mol Ther
, vol.17
, pp. 697-706
-
-
Zamarin, D.1
Martinez-Sobrido, L.2
Kelly, K.3
Mansour, M.4
Sheng, G.5
Vigil, A.6
Garcia-Sastre, A.7
Palese, P.8
Fong, Y.9
-
81
-
-
76349119010
-
Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma
-
PMID:19809404
-
Altomonte J, Marozin S, Schmid RM, Ebert O. Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther 2010; 18:275-84; PMID:19809404; http://dx. doi. org/10. 1038/mt. 2009. 231
-
(2010)
Mol Ther
, vol.18
, pp. 275-284
-
-
Altomonte, J.1
Marozin, S.2
Schmid, R.M.3
Ebert, O.4
-
82
-
-
77958059448
-
Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma
-
PMID:20858727
-
Silberhumer GR, Brader P, Wong J, Serganova IS, Gonen M, Gonzalez SJ, Blasberg R, Zamarin D, Fong Y. Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol Cancer Ther 2010; 9:2761-9; PMID:20858727; http://dx. doi. org/ 10. 1158/1535-7163. MCT-10-0090
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 2761-2769
-
-
Silberhumer, G.R.1
Brader, P.2
Wong, J.3
Serganova, I.S.4
Gonen, M.5
Gonzalez, S.J.6
Blasberg, R.7
Zamarin, D.8
Fong, Y.9
-
83
-
-
80053007260
-
Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer
-
PMID:21928411
-
Li P, Chen CH, Li S, Givi B, Yu Z, Zamarin D, Palese P, Fong Y, Wong RJ. Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer. Head Neck 2011; 33:1394-9; PMID:21928411; http://dx. doi. org/10. 1002/ hed. 21609
-
(2011)
Head Neck
, vol.33
, pp. 1394-1399
-
-
Li, P.1
Chen, C.H.2
Li, S.3
Givi, B.4
Yu, Z.5
Zamarin, D.6
Palese, P.7
Fong, Y.8
Wong, R.J.9
-
84
-
-
84897476768
-
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy
-
PMID:24598590
-
Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 2014; 6:226ra32; PMID:24598590; http://dx. doi. org/ 10. 1126/scitranslmed. 3008095
-
(2014)
Sci Transl Med
, vol.6
-
-
Zamarin, D.1
Holmgaard, R.B.2
Subudhi, S.K.3
Park, J.S.4
Mansour, M.5
Palese, P.6
Merghoub, T.7
Wolchok, J.D.8
Allison, J.P.9
-
86
-
-
84893773791
-
Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection
-
PMID:24384773
-
Buijs PR, van Eijck CH, Hofland LJ, Fouchier RA, van den Hoogen BG. Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection. Cancer Gene Ther 2014; 21:24-30; PMID:24384773; http://dx. doi. org/ 10. 1038/cgt. 2013. 78
-
(2014)
Cancer Gene Ther
, vol.21
, pp. 24-30
-
-
Buijs, P.R.1
van Eijck, C.H.2
Hofland, L.J.3
Fouchier, R.A.4
van den Hoogen, B.G.5
-
87
-
-
84927176136
-
Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy
-
PMID:25257305
-
Buijs PR, van Amerongen G, van Nieuwkoop S, Bestebroer TM, van Run PR, Kuiken T, Fouchier RA, van Eijck CH, van den Hoogen BG. Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy. Cancer Gene Ther 2014; 21(11):463-71; PMID:25257305; http://dx. doi. org/10. 1038/cgt. 2014. 51
-
(2014)
Cancer Gene Ther
, vol.21
, Issue.11
, pp. 463-471
-
-
Buijs, P.R.1
van Amerongen, G.2
van Nieuwkoop, S.3
Bestebroer, T.M.4
van Run, P.R.5
Kuiken, T.6
Fouchier, R.A.7
van Eijck, C.H.8
van den Hoogen, B.G.9
-
88
-
-
84869217555
-
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer
-
PMID:23052398
-
Hastie E, Grdzelishvili VZ. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol 2012; 93:2529-45; PMID:23052398; http://dx. doi. org/10. 1099/ vir. 0. 046672-0
-
(2012)
J Gen Virol
, vol.93
, pp. 2529-2545
-
-
Hastie, E.1
Grdzelishvili, V.Z.2
-
89
-
-
0023724709
-
A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection
-
PMID:2845825
-
Quiroz E, Moreno N, Peralta PH, Tesh RB. A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection. Am J Trop Med Hyg 1988; 39:312-4; PMID:2845825
-
(1988)
Am J Trop Med Hyg
, vol.39
, pp. 312-314
-
-
Quiroz, E.1
Moreno, N.2
Peralta, P.H.3
Tesh, R.B.4
-
90
-
-
0033929057
-
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
-
PMID:10888934
-
Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6:821-5; PMID:10888934; http://dx. doi. org/10. 1038/77558
-
(2000)
Nat Med
, vol.6
, pp. 821-825
-
-
Stojdl, D.F.1
Lichty, B.2
Knowles, S.3
Marius, R.4
Atkins, H.5
Sonenberg, N.6
Bell, J.C.7
-
91
-
-
27944432605
-
VSV-tumor selective replication and protein translation
-
PMID:16299531
-
Barber GN. VSV-tumor selective replication and protein translation. Oncogene 2005; 24:7710-9; PMID:16299531; http://dx. doi. org/10. 1038/sj. onc. 1209042
-
(2005)
Oncogene
, vol.24
, pp. 7710-7719
-
-
Barber, G.N.1
-
92
-
-
44949129955
-
Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation
-
PMID:18417567
-
Oliere S, Arguello M, Mesplede T, Tumilasci V, Nakhaei P, Stojdl D, Sonenberg N, Bell J, Hiscott J. Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation. J Virol 2008; 82:5735-49; PMID:18417567; http://dx. doi. org/10. 1128/JVI. 02601-07
-
(2008)
J Virol
, vol.82
, pp. 5735-5749
-
-
Oliere, S.1
Arguello, M.2
Mesplede, T.3
Tumilasci, V.4
Nakhaei, P.5
Stojdl, D.6
Sonenberg, N.7
Bell, J.8
Hiscott, J.9
-
93
-
-
84907247400
-
Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs
-
PMID:24219832
-
LeBlanc AK, Naik S, Galyon GD, Jenks N, Steele M, Peng KW, Federspiel MJ, Donnell R, Russell SJ. Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs. Hum Gene Ther Clin Dev 2013; 24:174-81; PMID:24219832; http://dx. doi. org/10. 1089/humc. 2013. 165
-
(2013)
Hum Gene Ther Clin Dev
, vol.24
, pp. 174-181
-
-
LeBlanc, A.K.1
Naik, S.2
Galyon, G.D.3
Jenks, N.4
Steele, M.5
Peng, K.W.6
Federspiel, M.J.7
Donnell, R.8
Russell, S.J.9
-
94
-
-
77950957568
-
Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates
-
PMID:19911974
-
Jenks N, Myers R, Greiner SM, Thompson J, Mader EK, Greenslade A, Griesmann GE, Federspiel MJ, Rakela J, Borad MJ, et al. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther 2010; 21:451-62; PMID:19911974; http://dx. doi. org/ 10. 1089/hum. 2009. 111
-
(2010)
Hum Gene Ther
, vol.21
, pp. 451-462
-
-
Jenks, N.1
Myers, R.2
Greiner, S.M.3
Thompson, J.4
Mader, E.K.5
Greenslade, A.6
Griesmann, G.E.7
Federspiel, M.J.8
Rakela, J.9
Borad, M.J.10
-
95
-
-
85017728851
-
Early findings from a comparative oncology study evaluating systemic VSV therapy in client owned dogs with spontaneous hematologic malignancies
-
th International Conference on Oncolytic Virus Therapeutics 2014
-
(2014)
th International Conference on Oncolytic Virus Therapeutics
-
-
Naik, S.1
LeBlanc, A.K.2
Galyon, G.D.3
Frazier, S.4
Jenks, N.5
Steele, M.6
Peng, K.W.7
Federspiel, M.8
Donnell, R.9
Russell, S.J.10
-
96
-
-
79961192841
-
A recombinant vesicular stomatitis virus bearing a lethal mutation in the glycoprotein gene uncovers a second site suppressor that restores fusion
-
PMID:21680501
-
Stanifer ML, Cureton DK, Whelan SP. A recombinant vesicular stomatitis virus bearing a lethal mutation in the glycoprotein gene uncovers a second site suppressor that restores fusion. J Virol 2011; 85:8105-15; PMID:21680501; http://dx. doi. org/ 10. 1128/JVI. 00735-11
-
(2011)
J Virol
, vol.85
, pp. 8105-8115
-
-
Stanifer, M.L.1
Cureton, D.K.2
Whelan, S.P.3
-
97
-
-
84869049988
-
Second-site mutations selected in transcriptional regulatory sequences compensate for engineered mutations in the vesicular stomatitis virus nucleocapsid protein
-
PMID:22875970
-
Harouaka D, Wertz GW. Second-site mutations selected in transcriptional regulatory sequences compensate for engineered mutations in the vesicular stomatitis virus nucleocapsid protein. J Virol 2012; 86:11266-75; PMID:22875970; http://dx. doi. org/ 10. 1128/JVI. 01238-12
-
(2012)
J Virol
, vol.86
, pp. 11266-11275
-
-
Harouaka, D.1
Wertz, G.W.2
-
98
-
-
0035450256
-
Mechanisms of loss of foreign gene expression in recombinant vesicular stomatitis viruses
-
PMID:11531419
-
Quinones-Kochs MI, Schnell MJ, Buonocore L, Rose JK. Mechanisms of loss of foreign gene expression in recombinant vesicular stomatitis viruses. Virology 2001; 287:427-35; PMID:11531419; http://dx. doi. org/10. 1006/viro. 2001. 1058
-
(2001)
Virology
, vol.287
, pp. 427-435
-
-
Quinones-Kochs, M.I.1
Schnell, M.J.2
Buonocore, L.3
Rose, J.K.4
-
99
-
-
33748640372
-
Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line
-
PMID:16912309
-
Gao Y, Whitaker-Dowling P, Watkins SC, Griffin JA, Bergman I. Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line. J Virol 2006; 80:8603-12; PMID:16912309; http://dx. doi. org/ 10. 1128/JVI. 00142-06
-
(2006)
J Virol
, vol.80
, pp. 8603-8612
-
-
Gao, Y.1
Whitaker-Dowling, P.2
Watkins, S.C.3
Griffin, J.A.4
Bergman, I.5
-
100
-
-
84865306234
-
A single amino acid change resulting in loss of fluorescence of eGFP in a viral fusion protein confers fitness and growth advantage to the recombinant vesicular stomatitis virus
-
PMID:22832124
-
Dinh PX, Panda D, Das PB, Das SC, Das A, Pattnaik AK. A single amino acid change resulting in loss of fluorescence of eGFP in a viral fusion protein confers fitness and growth advantage to the recombinant vesicular stomatitis virus. Virology 2012; 432:460-9; PMID:22832124; http://dx. doi. org/10. 1016/j. virol. 2012. 07. 004
-
(2012)
Virology
, vol.432
, pp. 460-469
-
-
Dinh, P.X.1
Panda, D.2
Das, P.B.3
Das, S.C.4
Das, A.5
Pattnaik, A.K.6
-
101
-
-
84875744451
-
Hand, foot, and mouth disease: Current scenario and Indian perspective
-
PMID:23442455
-
Sarma N. Hand, foot, and mouth disease: current scenario and Indian perspective. Indian J Dermatol Venereol Leprol 2013; 79:165-75; PMID:23442455; http://dx. doi. org/10. 4103/0378-6323. 107631
-
(2013)
Indian J Dermatol Venereol Leprol
, vol.79
, pp. 165-175
-
-
Sarma, N.1
-
102
-
-
0024425960
-
The complete nucleotide sequence of coxsackievirus A21
-
PMID:2584950
-
Hughes PJ, North C, Minor PD, Stanway G. The complete nucleotide sequence of coxsackievirus A21. J Gen Virol 1989; 70(Pt 11):2943-52; PMID:2584950; http://dx. doi. org/10. 1099/0022- 1317-70-11-2943
-
(1989)
J Gen Virol
, vol.70
, pp. 2943-2952
-
-
Hughes, P.J.1
North, C.2
Minor, P.D.3
Stanway, G.4
-
103
-
-
0031008583
-
Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry
-
PMID:9151867
-
Shafren DR, Dorahy DJ, Ingham RA, Burns GF, Barry RD. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol 1997; 71:4736-43; PMID:9151867
-
(1997)
J Virol
, vol.71
, pp. 4736-4743
-
-
Shafren, D.R.1
Dorahy, D.J.2
Ingham, R.A.3
Burns, G.F.4
Barry, R.D.5
-
104
-
-
1642453768
-
Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21
-
PMID:14734451
-
Shafren DR, Au GG, Nguyen T, Newcombe NG, Haley ES, Beagley L, Johansson ES, Hersey P, Barry RD. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res 2004; 10:53-60; PMID:14734451; http://dx. doi. org/10. 1158/1078- 0432. CCR-0690-3
-
(2004)
Clin Cancer Res
, vol.10
, pp. 53-60
-
-
Shafren, D.R.1
Au, G.G.2
Nguyen, T.3
Newcombe, N.G.4
Haley, E.S.5
Beagley, L.6
Johansson, E.S.7
Hersey, P.8
Barry, R.D.9
-
106
-
-
0024519677
-
Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily
-
PMID:2538245
-
Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 1989; 56:855-65; PMID:2538245; http://dx. doi. org/10. 1016/0092- 8674(89)90690-9
-
(1989)
Cell
, vol.56
, pp. 855-865
-
-
Mendelsohn, C.L.1
Wimmer, E.2
Racaniello, V.R.3
-
107
-
-
4344646381
-
Poliovirus receptor CD155-targeted oncolysis of glioma
-
PMID:15279713
-
Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD, Gromeier M. Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro Oncol 2004; 6:208-17; PMID:15279713; http://dx. doi. org/ 10. 1215/S1152851703000577
-
(2004)
Neuro Oncol
, vol.6
, pp. 208-217
-
-
Merrill, M.K.1
Bernhardt, G.2
Sampson, J.H.3
Wikstrand, C.J.4
Bigner, D.D.5
Gromeier, M.6
-
108
-
-
78049452625
-
MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus
-
PMID:20648000
-
Goetz C, Everson RG, Zhang LC, Gromeier M. MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus. Mol Ther 2010; 18:1937- 46; PMID:20648000; http://dx. doi. org/10. 1038/ mt. 2010. 145
-
(2010)
Mol Ther
, vol.18
, pp. 1937-1946
-
-
Goetz, C.1
Everson, R.G.2
Zhang, L.C.3
Gromeier, M.4
-
109
-
-
0032935027
-
Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence
-
PMID:9882296
-
Gromeier M, Bossert B, Arita M, Nomoto A, Wimmer E. Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence. J Virol 1999; 73:958-64; PMID:9882296
-
(1999)
J Virol
, vol.73
, pp. 958-964
-
-
Gromeier, M.1
Bossert, B.2
Arita, M.3
Nomoto, A.4
Wimmer, E.5
-
110
-
-
54949090721
-
Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype
-
PMID:18766173
-
Dobrikova EY, Broadt T, Poiley-Nelson J, Yang X, Soman G, Giardina S, Harris R, Gromeier M. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Mol Ther 2008; 16:1865-72; PMID:18766173; http://dx. doi. org/10. 1038/ mt. 2008. 184
-
(2008)
Mol Ther
, vol.16
, pp. 1865-1872
-
-
Dobrikova, E.Y.1
Broadt, T.2
Poiley-Nelson, J.3
Yang, X.4
Soman, G.5
Giardina, S.6
Harris, R.7
Gromeier, M.8
-
112
-
-
84857880081
-
Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus: Rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis
-
PMID:22171271
-
Dobrikova EY, Goetz C, Walters RW, Lawson SK, Peggins JO, Muszynski K, Ruppel S, Poole K, Giardina SL, Vela EM, et al. Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus: rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis. J Virol 2012; 86:2750-9; PMID:22171271; http://dx. doi. org/10. 1128/ JVI. 06427-11
-
(2012)
J Virol
, vol.86
, pp. 2750-2759
-
-
Dobrikova, E.Y.1
Goetz, C.2
Walters, R.W.3
Lawson, S.K.4
Peggins, J.O.5
Muszynski, K.6
Ruppel, S.7
Poole, K.8
Giardina, S.L.9
Vela, E.M.10
-
113
-
-
79960397102
-
A host-specific, temperature- sensitive translation defect determines the attenuation phenotype of a human rhinovirus/poliovirus chimera, PV1(RIPO)
-
PMID:21561914
-
Jahan N, Wimmer E, Mueller S. A host-specific, temperature- sensitive translation defect determines the attenuation phenotype of a human rhinovirus/poliovirus chimera, PV1(RIPO). J Virol 2011; 85:7225-35; PMID:21561914; http://dx. doi. org/10. 1128/ JVI. 01804-09
-
(2011)
J Virol
, vol.85
, pp. 7225-7235
-
-
Jahan, N.1
Wimmer, E.2
Mueller, S.3
-
114
-
-
36048935105
-
Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers
-
PMID:17971529
-
Reddy PS, Burroughs KD, Hales LM, Ganesh S, Jones BH, Idamakanti N, Hay C, Li SS, Skele KL, Vasko AJ, et al. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst 2007; 99:1623-33; PMID:17971529; http://dx. doi. org/ 10. 1093/jnci/djm198
-
(2007)
J Natl Cancer Inst
, vol.99
, pp. 1623-1633
-
-
Reddy, P.S.1
Burroughs, K.D.2
Hales, L.M.3
Ganesh, S.4
Jones, B.H.5
Idamakanti, N.6
Hay, C.7
Li, S.S.8
Skele, K.L.9
Vasko, A.J.10
-
115
-
-
84880559818
-
Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer
-
PMID:23739064
-
Poirier JT, Dobromilskaya I, Moriarty WF, Peacock CD, Hann CL, Rudin CM. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. J Natl Cancer Inst 2013; 105:1059-65; PMID:23739064; http://dx. doi. org/10. 1093/jnci/ djt130
-
(2013)
J Natl Cancer Inst
, vol.105
, pp. 1059-1065
-
-
Poirier, J.T.1
Dobromilskaya, I.2
Moriarty, W.F.3
Peacock, C.D.4
Hann, C.L.5
Rudin, C.M.6
-
116
-
-
77955122126
-
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program
-
PMID:20582972
-
Morton CL, Houghton PJ, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Wu J, Smith MA. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatric Blood Cancer 2010; 55:295-303; PMID:20582972; http://dx. doi. org/10. 1002/pbc. 22535
-
(2010)
Pediatric Blood Cancer
, vol.55
, pp. 295-303
-
-
Morton, C.L.1
Houghton, P.J.2
Kolb, E.A.3
Gorlick, R.4
Reynolds, C.P.5
Kang, M.H.6
Maris, J.M.7
Keir, S.T.8
Wu, J.9
Smith, M.A.10
-
117
-
-
79951649714
-
A single intravenous injection of oncolytic picornavirus SVV- 001 eliminates medulloblastomas in primary tumorbased orthotopic xenograft mouse models
-
PMID:21075780
-
Yu L, Baxter PA, Zhao X, Liu Z, Wadhwa L, Zhang Y, Su JM, Tan X, Yang J, Adesina A, et al. A single intravenous injection of oncolytic picornavirus SVV- 001 eliminates medulloblastomas in primary tumorbased orthotopic xenograft mouse models. Neuro Oncol 2011; 13:14-27; PMID:21075780; http://dx. doi. org/10. 1093/neuonc/noq148
-
(2011)
Neuro Oncol
, vol.13
, pp. 14-27
-
-
Yu, L.1
Baxter, P.A.2
Zhao, X.3
Liu, Z.4
Wadhwa, L.5
Zhang, Y.6
Su, J.M.7
Tan, X.8
Yang, J.9
Adesina, A.10
-
118
-
-
84883168783
-
Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumorbased orthotopic xenograft mouse models of pediatric glioma
-
PMID:23658322
-
Liu Z, Zhao X, Mao H, Baxter PA, Huang Y, Yu L, Wadhwa L, Su JM, Adesina A, Perlaky L, et al. Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumorbased orthotopic xenograft mouse models of pediatric glioma. Neuro Oncol 2013; 15:1173-85; PMID:23658322; http://dx. doi. org/10. 1093/neuonc/ not065
-
(2013)
Neuro Oncol
, vol.15
, pp. 1173-1185
-
-
Liu, Z.1
Zhao, X.2
Mao, H.3
Baxter, P.A.4
Huang, Y.5
Yu, L.6
Wadhwa, L.7
Su, J.M.8
Adesina, A.9
Perlaky, L.10
-
119
-
-
79951821209
-
Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features
-
PMID:21304001
-
Rudin CM, Poirier JT, Senzer NN, Stephenson J, Jr., Loesch D, Burroughs KD, Reddy PS, Hann CL, Hallenbeck PL. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin Cancer Res 2011; 17:888-95; PMID:21304001; http://dx. doi. org/10. 1158/1078- 0432. CCR-10-1706
-
(2011)
Clin Cancer Res
, vol.17
, pp. 888-895
-
-
Rudin, C.M.1
Poirier, J.T.2
Senzer, N.N.3
Stephenson, J.4
Loesch, D.5
Burroughs, K.D.6
Reddy, P.S.7
Hann, C.L.8
Hallenbeck, P.L.9
-
120
-
-
84925352074
-
Phase I trial of seneca valley virus (NTX-010) in children with relapsed/refractory solid tumors: A report of the children's oncology group
-
May
-
Burke MJ, Ahern C, Weigel BJ, Poirier JT, Rudin CM, Chen Y, Cripe TP, Bernhardt MB, Blaney SM. Phase I trial of seneca valley virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the children's oncology group. Pediatr Blood Cancer. 2015 May; 62(5):743-50.
-
(2015)
Pediatr Blood Cancer.
, vol.62
, Issue.5
, pp. 743-750
-
-
Burke, M.J.1
Ahern, C.2
Weigel, B.J.3
Poirier, J.T.4
Rudin, C.M.5
Chen, Y.6
Cripe, T.P.7
Bernhardt, M.B.8
Blaney, S.M.9
-
121
-
-
43049154506
-
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines
-
PMID:18468462
-
Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008; 28:710-22; PMID:18468462; http://dx. doi. org/10. 1016/j. immuni. 2008. 02. 020
-
(2008)
Immunity
, vol.28
, pp. 710-722
-
-
Miller, J.D.1
van der Most, R.G.2
Akondy, R.S.3
Glidewell, J.T.4
Albott, S.5
Masopust, D.6
Murali-Krishna, K.7
Mahar, P.L.8
Edupuganti, S.9
Lalor, S.10
-
122
-
-
42049121876
-
Enhancing poxvirus oncolytic effects through increased spread and immune evasion
-
PMID:18381410
-
Kirn DH, Wang Y, Liang W, Contag CH, Thorne SH. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res 2008; 68:2071-5; PMID:18381410; http://dx. doi. org/10. 1158/0008-5472. CAN-07-6515
-
(2008)
Cancer Res
, vol.68
, pp. 2071-2075
-
-
Kirn, D.H.1
Wang, Y.2
Liang, W.3
Contag, C.H.4
Thorne, S.H.5
-
123
-
-
36049009021
-
Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963
-
PMID:17965776
-
Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, Brown C, Werier J, Cho JH, Lee DE, et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 2007; 117:3350- 8; PMID:17965776; http://dx. doi. org/10. 1172/ JCI32727
-
(2007)
J Clin Invest
, vol.117
, pp. 3350-3358
-
-
Thorne, S.H.1
Hwang, T.H.2
O'Gorman, W.E.3
Bartlett, D.L.4
Sei, S.5
Kanji, F.6
Brown, C.7
Werier, J.8
Cho, J.H.9
Lee, D.E.10
-
124
-
-
0033950819
-
Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant
-
PMID:10678358
-
Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR, Bartlett DL. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 2000; 7:66-73; PMID:10678358; http://dx. doi. org/ 10. 1038/sj. cgt. 7700075
-
(2000)
Cancer Gene Ther
, vol.7
, pp. 66-73
-
-
Puhlmann, M.1
Brown, C.K.2
Gnant, M.3
Huang, J.4
Libutti, S.K.5
Alexander, H.R.6
Bartlett, D.L.7
-
125
-
-
38049017526
-
Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus
-
PMID:18162040
-
Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 2007; 4:e353; PMID:18162040; http://dx. doi. org/ 10. 1371/journal. pmed. 0040353
-
(2007)
PLoS Med
, vol.4
-
-
Kirn, D.H.1
Wang, Y.2
Le Boeuf, F.3
Bell, J.4
Thorne, S.H.5
-
126
-
-
0024205331
-
Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene
-
PMID:3184271
-
Shida H, Hinuma Y, Hatanaka M, Morita M, Kidokoro M, Suzuki K, Maruyama T, Takahashi-Nishimaki F, Sugimoto M, Kitamura R, et al. Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene. J Virol 1988; 62:4474-80; PMID:3184271
-
(1988)
J Virol
, vol.62
, pp. 4474-4480
-
-
Shida, H.1
Hinuma, Y.2
Hatanaka, M.3
Morita, M.4
Kidokoro, M.5
Suzuki, K.6
Maruyama, T.7
Takahashi-Nishimaki, F.8
Sugimoto, M.9
Kitamura, R.10
-
127
-
-
0016066489
-
Immunotherapy of malignant melanoma with vaccinia virus
-
PMID:4828533
-
Roenigk HH, Jr., Deodhar S, St Jacques R, Burdick K. Immunotherapy of malignant melanoma with vaccinia virus. Arch Dermatol 1974; 109:668-73; PMID:4828533; http://dx. doi. org/10. 1001/ archderm. 1974. 01630050014003
-
(1974)
Arch Dermatol
, vol.109
, pp. 668-673
-
-
Roenigk, H.H.1
Deodhar, S.2
St Jacques, R.3
Burdick, K.4
-
128
-
-
0028233204
-
Intravesical gene therapy: In vivo gene transfer using recombinant vaccinia virus vectors
-
PMID:8012943
-
Lee SS, Eisenlohr LC, McCue PA, Mastrangelo MJ, Lattime EC. Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res 1994; 54:3325-8; PMID:8012943
-
(1994)
Cancer Res
, vol.54
, pp. 3325-3328
-
-
Lee, S.S.1
Eisenlohr, L.C.2
McCue, P.A.3
Mastrangelo, M.J.4
Lattime, E.C.5
-
129
-
-
78649519141
-
Oncolytic vaccinia virus: A silver bullet?
-
PMID:21105770
-
Lusky M, Erbs P, Foloppe J, Acres RB. Oncolytic vaccinia virus: a silver bullet? Expert Rev Vaccines 2010; 9:1353-6; PMID:21105770; http://dx. doi. org/ 10. 1586/erv. 10. 137
-
(2010)
Expert Rev Vaccines
, vol.9
, pp. 1353-1356
-
-
Lusky, M.1
Erbs, P.2
Foloppe, J.3
Acres, R.B.4
-
130
-
-
85051838091
-
Tracking of tumor cell colonization, in-patient replication, and oncolysis by GL-ONC1 employed in a phase I/II virotherapy study on patients with peritoneal carcinomatosis
-
th International Conference on Oncolytic Virus Therapeutics 2014
-
(2014)
th International Conference on Oncolytic Virus Therapeutics
-
-
Lauer, U.M.1
Beil, J.2
Berchtold, S.3
Zimmermann, M.4
Koppenhöfer, U.5
Bitzer, M.6
Malek, N.P.7
Glatzle, J.8
Königsrainer, A.9
Möhle, R.10
-
132
-
-
0037458734
-
Smallpox vaccination and adverse reactions. Guidance for clinicians
-
PMID:12617510
-
Cono J, Casey CG, Bell DM. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep 2003; 52:1-28; PMID:12617510
-
(2003)
MMWR Recomm Rep
, vol.52
, pp. 1-28
-
-
Cono, J.1
Casey, C.G.2
Bell, D.M.3
-
133
-
-
80052406557
-
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
-
PMID:21886163
-
Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011; 477:99-102; PMID:21886163; http://dx. doi. org/10. 1038/nature10358
-
(2011)
Nature
, vol.477
, pp. 99-102
-
-
Breitbach, C.J.1
Burke, J.2
Jonker, D.3
Stephenson, J.4
Haas, A.R.5
Chow, L.Q.6
Nieva, J.7
Hwang, T.H.8
Moon, A.9
Patt, R.10
-
134
-
-
84899063595
-
Genome scale patterns of recombination between coinfecting vaccinia viruses
-
PMID:24574414
-
Qin L, Evans DH. Genome scale patterns of recombination between coinfecting vaccinia viruses. J Virol 2014; 88:5277-86; PMID:24574414; http://dx. doi. org/10. 1128/JVI. 00022-14
-
(2014)
J Virol
, vol.88
, pp. 5277-5286
-
-
Qin, L.1
Evans, D.H.2
-
135
-
-
0002402597
-
Reovirus infections in human volunteers
-
PMID:13974840
-
Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am J Hyg 1963; 77:29-37; PMID:13974840
-
(1963)
Am J Hyg
, vol.77
, pp. 29-37
-
-
Rosen, L.1
Evans, H.E.2
Spickard, A.3
-
136
-
-
17044431352
-
Prevalence of reovirusspecific antibodies in young children in Nashville, Tennessee
-
PMID:15776366
-
Tai JH, Williams JV, Edwards KM, Wright PF, Crowe JE, Jr., Dermody TS. Prevalence of reovirusspecific antibodies in young children in Nashville, Tennessee. J Infect Dis 2005; 191:1221-4; PMID:15776366; http://dx. doi. org/10. 1086/428911
-
(2005)
J Infect Dis
, vol.191
, pp. 1221-1224
-
-
Tai, J.H.1
Williams, J.V.2
Edwards, K.M.3
Wright, P.F.4
Crowe, J.E.5
Dermody, T.S.6
-
137
-
-
84871390091
-
Reovirus: A targeted therapeutic-progress and potential
-
PMID:23038811
-
Maitra R, Ghalib MH, Goel S. Reovirus: a targeted therapeutic-progress and potential. Mol Cancer Res 2012; 10:1514-25; PMID:23038811; http://dx. doi. org/10. 1158/1541-7786. MCR-12-0157
-
(2012)
Mol Cancer Res
, vol.10
, pp. 1514-1525
-
-
Maitra, R.1
Ghalib, M.H.2
Goel, S.3
-
138
-
-
27944459718
-
Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer
-
PMID:16299532
-
Shmulevitz M, Marcato P, Lee PW. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene 2005; 24:7720-8; PMID:16299532; http://dx. doi. org/ 10. 1038/sj. onc. 1209041
-
(2005)
Oncogene
, vol.24
, pp. 7720-7728
-
-
Shmulevitz, M.1
Marcato, P.2
Lee, P.W.3
-
139
-
-
34547125563
-
Uncoating reo: Uncovering the steps critical for oncolysis
-
PMID:17646836
-
Lemay G, Tumilasci V, Hiscott J. Uncoating reo: uncovering the steps critical for oncolysis. Mol Ther 2007; 15:1406-7; PMID:17646836; http://dx. doi. org/10. 1038/sj. mt. 6300242
-
(2007)
Mol Ther
, vol.15
, pp. 1406-1407
-
-
Lemay, G.1
Tumilasci, V.2
Hiscott, J.3
-
140
-
-
41949127866
-
Transient infection of freshly isolated human colorectal tumor cells by reovirus T3D intermediate subviral particles
-
PMID:18259212
-
van Houdt WJ, Smakman N, van den Wollenberg DJ, Emmink BL, Veenendaal LM, van Diest PJ, Hoeben RC, Borel Rinkes IH, Kranenburg O. Transient infection of freshly isolated human colorectal tumor cells by reovirus T3D intermediate subviral particles. Cancer Gene Ther 2008; 15:284-92; PMID:18259212; http://dx. doi. org/10. 1038/cgt. 2008. 2
-
(2008)
Cancer Gene Ther
, vol.15
, pp. 284-292
-
-
van Houdt, W.J.1
Smakman, N.2
van den Wollenberg, D.J.3
Emmink, B.L.4
Veenendaal, L.M.5
van Diest, P.J.6
Hoeben, R.C.7
Borel Rinkes, I.H.8
Kranenburg, O.9
-
141
-
-
84868103303
-
Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A
-
PMID:23110175
-
van den Wollenberg DJ, Dautzenberg IJ, van den Hengel SK, Cramer SJ, de Groot RJ, Hoeben RC. Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A. PLoS One 2012; 7:e48064; PMID:23110175; http://dx. doi. org/10. 1371/journal. pone. 0048064
-
(2012)
PLoS One
, vol.7
-
-
van den Wollenberg, D.J.1
Dautzenberg, I.J.2
van den Hengel, S.K.3
Cramer, S.J.4
de Groot, R.J.5
Hoeben, R.C.6
-
143
-
-
77953539465
-
Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics
-
PMID:20223697
-
Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 2010; 21:91-8; PMID:20223697; http://dx. doi. org/ 10. 1016/j. cytogfr. 2010. 02. 006
-
(2010)
Cytokine Growth Factor Rev
, vol.21
, pp. 91-98
-
-
Harrington, K.J.1
Vile, R.G.2
Melcher, A.3
Chester, J.4
Pandha, H.S.5
-
144
-
-
84894380172
-
Evaluation of homogeneity and genetic stability of REOLYSIN (pelareorep) by complete genome sequencing of reovirus after large scale production
-
PMID:24419798
-
Chakrabarty R, Tran H, Fortin Y, Yu Z, Shen SH, Kolman J, Onions D, Voyer R, Hagerman A, Serl S, et al. Evaluation of homogeneity and genetic stability of REOLYSIN (pelareorep) by complete genome sequencing of reovirus after large scale production. Appl Microbiol Biotechnol 2014; 98:1763-70; PMID:24419798; http://dx. doi. org/10. 1007/s00253- 013-5499-0
-
(2014)
Appl Microbiol Biotechnol
, vol.98
, pp. 1763-1770
-
-
Chakrabarty, R.1
Tran, H.2
Fortin, Y.3
Yu, Z.4
Shen, S.H.5
Kolman, J.6
Onions, D.7
Voyer, R.8
Hagerman, A.9
Serl, S.10
-
146
-
-
0037279647
-
Replicative retroviral vectors for cancer gene therapy
-
PMID:12489026
-
Solly SK, Trajcevski S, Frisen C, Holzer GW, Nelson E, Clerc B, Abordo-Adesida E, Castro M, Lowenstein P, Klatzmann D. Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther 2003; 10:30-9; PMID:12489026; http://dx. doi. org/10. 1038/sj. cgt. 7700521
-
(2003)
Cancer Gene Ther
, vol.10
, pp. 30-39
-
-
Solly, S.K.1
Trajcevski, S.2
Frisen, C.3
Holzer, G.W.4
Nelson, E.5
Clerc, B.6
Abordo-Adesida, E.7
Castro, M.8
Lowenstein, P.9
Klatzmann, D.10
-
147
-
-
0034947740
-
Genomic stability of murine leukemia viruses containing insertions at the Env-3' untranslated region boundary
-
PMID:11435579
-
Logg CR, Logg A, Tai CK, Cannon PM, Kasahara N. Genomic stability of murine leukemia viruses containing insertions at the Env-3' untranslated region boundary. J Virol 2001; 75:6989-98; PMID:11435579; http://dx. doi. org/10. 1128/ JVI. 75. 15. 6989-6998. 2001
-
(2001)
J Virol
, vol.75
, pp. 6989-6998
-
-
Logg, C.R.1
Logg, A.2
Tai, C.K.3
Cannon, P.M.4
Kasahara, N.5
-
148
-
-
79952193873
-
Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma
-
PMID:20623247
-
Hlavaty J, Jandl G, Liszt M, Petznek H, Konig-Schuster M, Sedlak J, Egerbacher M, Weissenberger J, Salmons B, Gunzburg WH, et al. Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma. J Neurooncol 2011; 102:59-69; PMID:20623247; http://dx. doi. org/10. 1007/s11060- 010-0295-5
-
(2011)
J Neurooncol
, vol.102
, pp. 59-69
-
-
Hlavaty, J.1
Jandl, G.2
Liszt, M.3
Petznek, H.4
Konig-Schuster, M.5
Sedlak, J.6
Egerbacher, M.7
Weissenberger, J.8
Salmons, B.9
Gunzburg, W.H.10
-
149
-
-
84867077136
-
Design and selection of Toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression
-
PMID:22547150
-
Perez OD, Logg CR, Hiraoka K, Diago O, Burnett R, Inagaki A, Jolson D, Amundson K, Buckley T, Lohse D, et al. Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther 2012; 20:1689-98; PMID:22547150; http://dx. doi. org/10. 1038/mt. 2012. 83
-
(2012)
Mol Ther
, vol.20
, pp. 1689-1698
-
-
Perez, O.D.1
Logg, C.R.2
Hiraoka, K.3
Diago, O.4
Burnett, R.5
Inagaki, A.6
Jolson, D.7
Amundson, K.8
Buckley, T.9
Lohse, D.10
-
150
-
-
79960556047
-
Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma
-
PMID:21660062
-
Kawasaki Y, Tamamoto A, Takagi-Kimura M, Maeyama Y, Yamaoka N, Terada N, Okamura H, Kasahara N, Kubo S. Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma. Cancer Gene Ther 2011; 18:571-8; PMID:21660062; http://dx. doi. org/10. 1038/ cgt. 2011. 25
-
(2011)
Cancer Gene Ther
, vol.18
, pp. 571-578
-
-
Kawasaki, Y.1
Tamamoto, A.2
Takagi-Kimura, M.3
Maeyama, Y.4
Yamaoka, N.5
Terada, N.6
Okamura, H.7
Kasahara, N.8
Kubo, S.9
|